AstraZeneca Annual Report and 96 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 7 PROPERTY, PLANT AND EQUIPMENT Assets in Total Land and Plant and course of tangible buildings equipment construction assets $m $m $m $m Cost At 1 January 2003 3,145 6,612 1,298 11,055 Capital expenditure 67 215 964 1,246 Transfer of assets into use 510 915 1,425 Disposals and other movements 42 667 22 731 Exchange adjustments 448 906 133 1,487 At 31 December 2003 4,128 7,981 948 13,057 Capital expenditure 17 205 851 1,073 Transfer of assets into use 430 641 1,071 Disposals and other movements 55 335 6 396 Exchange adjustments 281 590 45 916 At 31 December 2004 4,801 9,082 767 14,650 Capital expenditure 13 150 669 832 Transfer of assets into use 257 594 851 Disposals and other movements 99 820 14 933 Exchange adjustments 482 971 91 1,544 At 31 December 2005 4,490 8,035 480 13,005 Depreciation At 1 January 2003 895 3,555 4,450 Charge for year 150 840 990 Disposals and other movements 35 553 588 Exchange adjustments 129 529 658 At 31 December 2003 1,139 4,371 5,510 Charge for year 172 749 921 Impairment 31 31 Disposals and other movements 37 302 339 Exchange adjustments 86 344 430 At 31 December 2004 1,360 5,193 6,553 Charge for year 166 799 965 Impairment 90 90 Disposals and other movements 53 794 847 Exchange adjustments 153 588 741 At 31 December 2005 1,320 4,700 6,020 Net book value At 31 December 2003 2,989 3,610 948 7,547 At 31 December 2004 3,441 3,889 767 8,097 At 31 December 2005 3,170 3,335 480 6,985 Impairment charges in 2005 relate to the write-down of assets associated with capacity reviews at manufacturing sites, primarily in the UK and France.
These were recognised in cost of sales in the income statement.
The impairment charge in 2004 was made to write off assets associated with Iressa.
This was recognised in cost of sales in the income statement.
Capital expenditure in the year of $832m 2004 $1,073m, 2003 $1,246m did not include any capitalised finance leases 2004 $nil, 2003 $nil.
